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It is well known that individuals with severe mental
illnesses (SMI), such as bipolar disorder (BD), major
depressive disorder (MDD), and schizophrenia, have
a twofold to threefold-higher risk of mortality rela-
tive to the general population and a markedly reduced
life expectancy (by 15 years on average). Although sui-
cide is unquestionably an important factor, replicated
evidence indicates that the main driver of excessive and
premature mortality in this population is cardiovascular
disease. The burden of cardiovascular disease is evi-
dent also in younger age groups, in which heart disease,
alongside other physical illnesses, accounts for most of
the excess mortality.
A major success story in medicine and public health
has been the progressive increase in life expectancy
throughout the world. Unfortunately, individuals with SMI
do not seem to be benefitting from this trend. Whereas
overall mortality rates have decreased sharply, including
from disparate conditions such as heart disease, cancer,
and infectious diseases, this decline is less evident in the
SMI population. For example, the incidence of myocardial
infarction has decreased by almost 50% in the general
population, but has barely changed in individuals with
SMI.
Several factors have been explored as possible media-
tors of cardiovascular disease and excess or premature
mortality in SMI. These factors include, but are not limited
to, metabolic and cardiac effects of medications (espe-
cially second-generation antipsychotics, antidepressants
and mood stabilizers); poor health habits (e.g., smoking
and alcohol abuse); and pathophysiological mechanisms
intrinsic to the systemic manifestations of mental dis-
orders.1,2 Nevertheless, inequalities in the access to health
care and in the quality of its delivery, especially regarding
detection and treatment of cardiovascular conditions and
other physical problems in people with SMI, have been
relatively less discussed.
The evidence is as clear as it is damning. Health systems
worldwide, including those in high-income countries, are
failing to provide optimal, evidence-based, cost-effective
interventions to this already vulnerable population. There is
replicated evidence that individuals with SMI are less likely
to have a regular source of primary medical care, even after
accounting for possible confounders such as age, gender,
race, education, income, and health insurance status.3
Neither psychiatrists nor general practitioners screen and
monitor individuals with SMI appropriately for metabolic risk
factors, despite recommendations from several agencies,
such as the U.S. Food and Drug Administration, American
Diabetes Association, and American Psychiatric Associa-
tion. For example, the rates of baseline metabolic assess-
ment in individuals taking second-generation antipsychotic
range from 8 to 30%, and only 8.8% of these patients
undergo metabolic monitoring as recommended. Individuals
with SMI are less likely to be prescribed cardiovascular
medications (e.g., antihypertensives, antihyperlipidemics)
and to receive smoking cessation advice, even though they
are twice as likely to smoke and to have obesity or diabetes.
Incredibly, individuals with SMI and a diagnosed myocardial
infarction have lower rates of surgical interventions, such
as revascularization, stenting, and bypass grafting, and
are less likely to receive cerebrovascular arteriography or
warfarin following a stroke. As a result, their mortality rate
after a myocardial infarction is three times higher than that
of the general population.4 In addition, people with SMI
are less likely to receive optimal clinical care for diabetes
and arthritis, and are less likely to receive routine cancer
screening.5 This pattern of poor access to quality health
care includes acute conditions as well, such as acute
appendicitis: people with SMI have been found to be
diagnosed later, experience more complications (e.g.,
gangrene or perforation of the appendix), and have worse
outcomes after surgery.6
Fortunately, evidence indicates that a number of simple
and cost-effective interventions can be used to address
these issues. Medical facilities providing integrated care,
which is sometimes as straightforward as having a psy-
chiatrist and a general practitioner on-site, have been
shown to yield better health outcomes. Preventive inter-
ventions, including but not limited to patient education,
smoking cessation, and weight-loss programs, have been
shown to work in the SMI population. Side effects of
psychotropic medications can also be managed effec-
tively through a combination of behavioral (e.g., dietary
and exercise counseling) and pharmacological interven-
tions (e.g., metformin, liraglutide).
One of the pressing issues of the 21st century is the
increase in income inequality over the past decades
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(or, in low- to middle-income countries, its persistence).
Recent epidemiological evidence suggests that the afore-
mentioned increase in life expectancy in the general
population may not be equally distributed, with lower
income/education cohorts displaying lower increases
or even decreases in life expectancy. Wealth, socio-
economic status, access to healthcare, mental illness,
and health outcomes are all inextricably linked. The extent
to which this larger context of social, economic, and
cultural trends is affecting the issue of excess/prema-
ture mortality in SMI, as well as the extent to which
these highly prevalent and chronic SMIs may actually
be driving the overall mortality gap, are relevant
questions that deserve to be explored with empirical
data. At a minimum, societal changes should inform
how the issue of excess/premature mortality in SMI is
framed, understood, and addressed, as advances in
science and technology are apparently benefiting only
the mentally healthy part of the population.7 A commit-
ment to first recognizing and then addressing the pro-
blem of excess/premature mortality in SMI is needed
from all actors, from healthcare policy makers through
healthcare providers to patient and peer advocacy
groups.
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